27 related articles for article (PubMed ID: 12810654)
1. Growth inhibition by anchorage-deficiency is associated with increased level but reduced phosphorylation of mutant p53.
Takahashi K; Suzuki K; Uehara Y; Ono T
Jpn J Cancer Res; 1992 Apr; 83(4):358-65. PubMed ID: 1506270
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines.
Mohammadian M; Zeynali S; Azarbaijani AF; Khadem Ansari MH; Kheradmand F
Res Pharm Sci; 2017 Dec; 12(6):517-525. PubMed ID: 29204180
[TBL] [Abstract][Full Text] [Related]
3. Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.
Chen C; Zhuang Y; Chen X; Chen X; Li D; Fan Y; Xu J; Chen Y; Wu L
Oncotarget; 2017 Feb; 8(6):10025-10036. PubMed ID: 28036294
[TBL] [Abstract][Full Text] [Related]
4. NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG.
Kasai S; Arakawa N; Okubo A; Shigeeda W; Yasuhira S; Masuda T; Akasaka T; Shibazaki M; Maesawa C
PLoS One; 2016; 11(4):e0153181. PubMed ID: 27045471
[TBL] [Abstract][Full Text] [Related]
5. Serines 440 and 467 in the Werner syndrome protein are phosphorylated by DNA-PK and affects its dynamics in response to DNA double strand breaks.
Kusumoto-Matsuo R; Ghosh D; Karmakar P; May A; Ramsden D; Bohr VA
Aging (Albany NY); 2014 Jan; 6(1):70-81. PubMed ID: 24429382
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 inhibitors and the reduction of anti-cancer drug resistance by non-genetic and genetic mechanisms.
Lu X; Wang L; Ruden DM
Pharmaceuticals (Basel); 2012 Aug; 5(9):890-8. PubMed ID: 24280696
[TBL] [Abstract][Full Text] [Related]
7. Molecular chaperone therapy- the future in cancer.
Shehzad AM; Dawani O; Munir S; Hussain SA
Infect Agent Cancer; 2012 Aug; 7(1):20. PubMed ID: 22889181
[No Abstract] [Full Text] [Related]
8. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.
Lu X; Xiao L; Wang L; Ruden DM
Biochem Pharmacol; 2012 Apr; 83(8):995-1004. PubMed ID: 22120678
[TBL] [Abstract][Full Text] [Related]
9. Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide.
Hatakeyama S; Sugihara K; Shibata TK; Nakayama J; Akama TO; Tamura N; Wong SM; Bobkov AA; Takano Y; Ohyama C; Fukuda M; Fukuda MN
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19587-92. PubMed ID: 22114188
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of HSP90 activity negatively modulates myogenic differentiation and cell survival in C2C12 cells.
Wagatsuma A; Shiozuka M; Kotake N; Takayuki K; Yusuke H; Mabuchi K; Matsuda R; Yamada S
Mol Cell Biochem; 2011 Dec; 358(1-2):265-80. PubMed ID: 21739150
[TBL] [Abstract][Full Text] [Related]
11. Heat shock proteins as emerging therapeutic targets.
Sõti C; Nagy E; Giricz Z; Vígh L; Csermely P; Ferdinandy P
Br J Pharmacol; 2005 Nov; 146(6):769-80. PubMed ID: 16170327
[TBL] [Abstract][Full Text] [Related]
12. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
[TBL] [Abstract][Full Text] [Related]
13. Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells.
Vasilevskaya IA; O'Dwyer PJ
Cancer Res; 1999 Aug; 59(16):3935-40. PubMed ID: 10463587
[TBL] [Abstract][Full Text] [Related]
14. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
Nimmanapalli R; O'Bryan E; Bhalla K
Cancer Res; 2001 Mar; 61(5):1799-804. PubMed ID: 11280726
[TBL] [Abstract][Full Text] [Related]
15. Structural diversity and biological relevance of benzenoid and atypical ansamycins and their congeners.
Skrzypczak N; Przybylski P
Nat Prod Rep; 2022 Sep; 39(9):1678-1704. PubMed ID: 35262153
[TBL] [Abstract][Full Text] [Related]
16. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.
Vasilevskaya IA; Rakitina TV; O'Dwyer PJ
Cancer Res; 2003 Jun; 63(12):3241-6. PubMed ID: 12810654
[TBL] [Abstract][Full Text] [Related]
17. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.
Vasilevskaya IA; Rakitina TV; O'Dwyer PJ
Mol Pharmacol; 2004 Jan; 65(1):235-43. PubMed ID: 14722256
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
